Amgenreported quarterly results that outpaced what Wall Street was expecting, and the company boosted its outlook for its full-year profit. But the company's shares declined in extended trading.
The pharmaceutical company earned $1.49 a share in its third quarter excluding one-time items, compared with $1.23 a share in the same period last year.
Sales for the most recent quarter reached $3.81 billion, down from $3.875 billion this time last year.
Analysts who follow Amgen expected the company to turn in a profit of $1.27 a share on sales of $3.793 billion, according to a consensus estimate rom Thomson Reuters.